For Immediate Release
Chicago, IL – August 1, 2013 – Zacks Equity Research highlights Gap, Inc. (GPS-Free Report) as the Bull of the Day and Amazon.com (AMZN-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on the Cubist Pharmaceuticals, Inc. (CBST-Free Report), Optimer Pharmaceuticals, Inc. (OPTR-Free Report) and Gilead Sciences Inc. (GILD-Free Report).
Here is a synopsis of all five stocks:
Everything appears to be going right for Gap, Inc. (GPS-Free Report) as it has become the darling retailer of Wall Street. Left for dead during the Great Recession, shares of this Zacks Rank #1 (Strong Buy) are at 10-year highs as monthly comps continue to come in stronger than expected.
Gap is a famous American retailer with three main brands: Gap, Old Navy and Banana Republic. It also operates Athleta, the women's athletic and yoga retailer which is a big part of its strategy to expand into the lucrative athletic wear market.
It has over 3100 company operated stores and 300 franchise stores. Each brand also has its own web site.
Gap is one of the few retailers which still reports monthly sales results. On July 11, it reported June results which were better than the analysts had expected, with same store sales jumping 7% compared to flat sales the year before.
Other retailers' results weren't as strong as many blamed the cooler than expected weather.
Old Navy, its largest segment, led the quarter as sales rose 13% due to summer promotions and strength in flip flops and dresses. Gap also showed strength as its sales rose 5% due to strong sales in denim and shorts.
Only Banana Republic struggled, as global sales fell 1% due to softness in the women's side of the business. Athleta is not yet big enough to be broken out separately.
Investors love Amazon.com (AMZN-Free Report) but analysts sent it into time out after it recently missed on second quarter earnings. This Zacks Rank #5 (Strong Sell) saw a loss in the quarter leaving many to ask: when will Amazon make money?
Amazon.com has its hands in many businesses. It is one of the Internet's largest retailers, a media company with publishing and video content, and a technology company with tablets, e-readers and cloud, among other things.
The company really can't be labeled in one category anymore. It is certainly more than just a book seller.
The company reported second quarter earnings on July 25 and missed the Zacks Consensus by 6 cents. It was expected to make $0.04 but posted a net loss of $7 million, or $0.02 per share.
Revenue rose 22% to $15.7 billion on strength in North America, especially in shoes and apparel and health and beauty. Customers are using the Prime program to buy items they once might have purchased at the local drugstore. Europe, however, remains weak.
Cubist Pharma Announces Acquisitions
In a bid to strengthen its antibiotics portfolio, Cubist Pharmaceuticals, Inc. (CBST-Free Report) announced its intention to acquire a couple of companies operating in the field. The first deal involves Optimer Pharmaceuticals, Inc. (OPTR-Free Report).
As per the terms of the deal, Optimer shareholders will receive $10.75 per share in cash (or $535 million) in addition to a contingent value right (CVR) for each share. The CVR will allow each shareholder to receive additional one-time cash payments of up to $5 per share in the event of certain sales milestones being achieved with respect to antibiotic Dificid. The CVRs are expected to be listed on the Nasdaq.
Cubist’s offer price of $15.75 per share (including the contingent payment) represents a premium of 18.5% to Optimer’s closing price on July 30. The deal, cleared by the boards of directors of both companies, is expected to close by Dec 31, 2013 and boost Cubist’s earnings in the first year following closure.
We note that Cubist and Optimer are no strangers to each other. The two companies co-promote Dificid in the U.S. treating patients suffering from clostridium difficile-associated diarrhea. Dificid is available in the U.S. since Jul 2011. The duration of the deal was initially two years and was consequently scheduled to expire at the end of this month. The companies have, however, extended the co-promotion deal by up to a year.
Cubist would gain full control of Dificid in the event of the merger materializing. Cubist has sufficient experience in marketing antibiotics. Cubicin, an antibiotic injection, is the growth engine at Cubist. Net sales of the product in the U.S. climbed 13.4% to $227.1 million in the second quarter of 2013. Cubicin performed well in international markets with sales of the drug climbing 31.6% to $15 million. The antibiotics pipeline at Cubist Pharma is also encouraging.
Cubist also announced its intention to purchase another antibiotics maker, Trius Therapeutics, for approximately $707 million. Including a contingent payment of $2.00 per share, the value of the deal, which is expected to close later in the year, can increase up to $818 million.
Cubist, a biopharmaceutical company, carries a Zacks Rank #3 (Hold). Companies such as Gilead Sciences Inc. (GILD-Free Report) (Zacks Rank #1) appear to be more attractive in the biopharma space.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks Investment Research
800-767-3771 ext. 9339
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
More From Zacks.com
- Finance Trading